according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.11 09/30/2023 2160728-00015 Date of first issue: 11/09/2017

### **SECTION 1. IDENTIFICATION**

Product name : Finasteride (3.25%) Formulation

Other means of identification : No data available

## Manufacturer or supplier's details

Company name of supplier : Organon & Co.

Address : 30 Hudson Street, 33nd floor

Jersey City, New Jersey, U.S.A 07302

Telephone : 1-551-430-6000 Emergency telephone : 1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

## Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

#### GHS classification in accordance with the Hazardous Products Regulations

Reproductive toxicity : Category 1B

Specific target organ toxicity

- repeated exposure (Oral)

: Category 1 (Testis)

#### **GHS** label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H360D May damage the unborn child.

H372 Causes damage to organs (Testis) through prolonged or

repeated exposure if swallowed.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust, fume, gas, mist, vapors or spray.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P280 Wear protective gloves, protective clothing, eye protection

and face protection.

#### Response:

P308 + P313 IF exposed or concerned: Get medical attention.

according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 2160728-00015 Date of first issue: 11/09/2017 2.11

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

Other hazards

None known.

#### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

## Components

Chemical name	Common	CAS-No.	Concentration (% w/w)
	Name/Synonym		
Cellulose	No data availa- ble	9004-34-6	>= 5 - < 10 *
Starch	Sago starch	9005-25-8	>= 5 - < 10 *
Finasteride	No data availa- ble	98319-26-7	>= 1 - < 5 *

<sup>\*</sup> Actual concentration or concentration range is withheld as a trade secret

## **SECTION 4. FIRST AID MEASURES**

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and May damage the unborn child.

delayed

Causes damage to organs through prolonged or repeated

exposure if swallowed.

Protection of first-aiders

First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.11 09/30/2023 2160728-00015 Date of first issue: 11/09/2017

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

Specific hazards during fire

fighting

Hazardous combustion prod-

ucts

Exposure to combustion products may be a hazard to health.

Carbon oxides Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

## **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec- :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust, fume, gas, mist, vapors or spray.

Do not swallow.

Avoid contact with eyes.

according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.11 09/30/2023 2160728-00015 Date of first issue: 11/09/2017

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Keep in properly labeled containers. Conditions for safe storage

> Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

**Explosives** Gases

#### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Total dust)	10 mg/m³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m³	CA BC OEL
		TWAEV (to- tal dust)	10 mg/m³	CA QC OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Starch	9005-25-8	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Total dust)	10 mg/m³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m³	CA BC OEL
		TWAEV (to- tal dust)	10 mg/m³	CA QC OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Finasteride	98319-26-7	TWA	0.5 μg/m3 (OEB 5)	Internal
		Wipe limit	5 μg/100 cm <sup>2</sup>	Internal

**Engineering measures** Use closed processing systems or containment technologies

> to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

> All engineering controls should be implemented by facility

according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 2160728-00015 Date of first issue: 11/09/2017 2.11

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems

are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into

the workplace.

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type Hand protection Particulates type

Material Chemical-resistant gloves

Remarks Consider double gloving.

Eye protection Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Work uniform or laboratory coat. Skin and body protection

> Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use. The effective operation of a facility should include review of

engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance solid

Color blue

Odor odorless

Odor Threshold No data available

No data available pΗ

according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.11 09/30/2023 2160728-00015 Date of first issue: 11/09/2017

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : No data available

## **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

Can react with strong oxidizing agents.

according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.11 09/30/2023 2160728-00015 Date of first issue: 11/09/2017

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition :

products

: No hazardous decomposition products are known.

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

### Information on likely routes of exposure

Skin contact Ingestion Eye contact

### **Acute toxicity**

Not classified based on available information.

#### **Product:**

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

#### **Components:**

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Finasteride:

Acute oral toxicity : LD50 (Rat): 373 - 828 mg/kg

LD50 (Mouse): 486 mg/kg

#### Skin corrosion/irritation

Not classified based on available information.

#### **Components:**

Finasteride:

Species : Rabbit

Result : No skin irritation

## Serious eye damage/eye irritation

Not classified based on available information.

according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.11 09/30/2023 2160728-00015 Date of first issue: 11/09/2017

#### **Components:**

Starch:

Species : Rabbit

Result : No eye irritation

Finasteride:

Species : Rabbit

Remarks : slight irritation

### Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

### Respiratory sensitization

Not classified based on available information.

### **Components:**

Starch:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

**Application Route: Ingestion** 

Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Finasteride:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Result: positive

according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.11 09/30/2023 2160728-00015 Date of first issue: 11/09/2017

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Alkaline elution assay

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Application Route: Oral

Result: negative

### Carcinogenicity

Not classified based on available information.

#### **Components:**

#### Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

#### Finasteride:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years

160 mg/kg body weight

Result : negative Target Organs : Testes

Remarks : Benign tumor(s)

Species : Mouse
Application Route : Ingestion
Exposure time : 19 month(s)
Result : negative
Target Organs : Testes

Remarks : Benign tumor(s)

#### Reproductive toxicity

May damage the unborn child.

## **Components:**

## Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.11 09/30/2023 2160728-00015 Date of first issue: 11/09/2017

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

**Application Route: Ingestion** 

Result: negative

Finasteride:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rabbit Application Route: Oral

Fertility: NOAEL: 80 mg/kg body weight

Result: No effects on fertility.

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Fertility: LOAEL: 80 mg/kg body weight

Result: positive

Remarks: These is no evidence that these findings are rele-

vant to humans.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Developmental Toxicity: LOAEL: 0.003 mg/kg body weight

Result: Teratogenic effects., Embryotoxic effects.

Test Type: Embryo-fetal development

Species: Monkey

Application Route: Ingestion

Developmental Toxicity: LOAEL: 2 mg/kg body weight

Result: Teratogenic effects.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

### STOT-single exposure

Not classified based on available information.

#### STOT-repeated exposure

Causes damage to organs (Testis) through prolonged or repeated exposure if swallowed.

## **Components:**

### Finasteride:

Routes of exposure : Ingestion Target Organs : Testis

Assessment : Causes damage to organs through prolonged or repeated

exposure.

according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.11 09/30/2023 2160728-00015 Date of first issue: 11/09/2017

### Repeated dose toxicity

## **Components:**

#### Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Starch:

Species : Rat

NOAEL : >= 2,000 mg/kg
Application Route : Skin contact
Exposure time : 28 Days

Method : OECD Test Guideline 410

Finasteride:

Species : Rat

NOAEL : 20 mg/kg

LOAEL : 40 mg/kg

Application Route : Oral

Exposure time : 1 y

Target Organs : Testis

Species : Dog
NOAEL : 45 mg/kg
Application Route : Oral
Exposure time : 1 y
Target Organs : Testis

## **Aspiration toxicity**

Not classified based on available information.

#### **Experience with human exposure**

### **Components:**

Finasteride:

Ingestion : Symptoms: breast tenderness, breast enlargement, impo-

tence, lip swelling, skin rash

#### **SECTION 12. ECOLOGICAL INFORMATION**

## **Ecotoxicity**

### **Components:**

#### Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.11 09/30/2023 2160728-00015 Date of first issue: 11/09/2017

Finasteride:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 20.4 mg/l

Exposure time: 96 h Method: FDA 4.11

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 17.8 mg/l

Exposure time: 48 h Method: FDA 4.08

Toxicity to algae/aquatic

plants

NOEC (Pseudokirchneriella subcapitata (green algae)): 49

mg/

Exposure time: 14 h Method: FDA 4.01

Toxicity to fish (Chronic tox-

icity)

NOEC (Oryzias latipes (Orange-red killifish)): 0.05 mg/l

Exposure time: 105 d

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.12 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

### Persistence and degradability

### **Components:**

Cellulose:

Biodegradability : Result: Readily biodegradable.

Finasteride:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 0 % Exposure time: 7 d Method: FDA 3.11

Stability in water : Hydrolysis: 0 %(5 d)

Method: FDA 3.09

### **Bioaccumulative potential**

#### **Components:**

Finasteride:

Partition coefficient: n-

: log Pow: 3.57

octanol/water

Mobility in soil
No data available

Other adverse effects

No data available

according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.11 09/30/2023 2160728-00015 Date of first issue: 11/09/2017

#### **SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods** 

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### **SECTION 14. TRANSPORT INFORMATION**

#### International Regulations

**UNRTDG** 

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Finasteride)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

**IATA-DGR** 

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

(Finasteride)

956

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo

aircraft)

Packing instruction (passen- : 956

ger aircraft)

Environmentally hazardous : yes

**IMDG-Code** 

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Finasteride)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### **Domestic regulation**

**TDG** 

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.11 09/30/2023 2160728-00015 Date of first issue: 11/09/2017

N.O.S.

(Finasteride)

Class : 9
Packing group : III
Labels : 9
ERG Code : 171

Marine pollutant : yes(Finasteride)

#### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### **SECTION 15. REGULATORY INFORMATION**

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### **SECTION 16. OTHER INFORMATION**

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table

2: OEL)

CA BC OEL : Canada. British Columbia OEL

CA QC OEL : Québec. Regulation respecting occupational health and safe-

ty, Schedule 1, Part 1: Permissible exposure values for air-

borne contaminants

ACGIH / TWA : 8-hour, time-weighted average
CA AB OEL / TWA : 8-hour Occupational exposure limit
CA BC OEL / TWA : 8-hour time weighted average

CA QC OEL / TWAEV : Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Or-

according to the Hazardous Products Regulations



# Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.11 09/30/2023 2160728-00015 Date of first issue: 11/09/2017

ganisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to

compile the Material Safety

**Data Sheet** 

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/30/2023 Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8